$ACAD News

Principal Accounting Officer At ACADIA Pharmaceuticals Sells $114K Of Stock

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $32

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. 2026 Q1 - Results - Earnings Call Presentation

Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower

ACADIA Pharmaceuticals Affirms FY2026 Sales Guidance of $1.220B-$1.280B vs $1.247B Est

ACADIA Pharmaceuticals Q1 EPS $0.02 Misses $0.05 Estimate, Sales $268.062M Miss $280.710M Estimate

Acadia Pharmaceuticals Launches DAYBUE STIX, New Powder Trofinetide Formulation For Flexible, Patient-Centered Rett Syndrome Treatment In U.S.

B of A Securities Upgrades ACADIA Pharmaceuticals to Buy, Maintains Price Target to $29

JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $34

Acadia Pharmaceuticals To Request Re-Examination Of European Medicines Agency Negative Opinion Findings In Trofinetide Treatment Of Rett Syndrome

Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker

TD Cowen Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $37

RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $30

Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $35

ACADIA Pharmaceuticals shares are trading lower after the company reported mixed Q4 financial results. Stifel lowered its price target on the stock from $25 to $24.

Stifel Maintains Hold on ACADIA Pharmaceuticals, Lowers Price Target to $24

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Surpasses $1 Billion Revenue Milestone in 2025, Beats Q4 EPS Estimates